腾盛博药-B2023 中期报告
Brii Biosciences Limited騰盛博藥生物科技有限公司 ()於開曼群島註冊成立的有限公司 股份代號 :2137 2023中期報告 2 4 6 25 45 46 48 50 51 52 68 騰盛博藥2018 HBV8,7002VirBiotechnology,Inc.VBIVaccines Inc.HBVHBVHBVHBV PPDMDDGABAAPAMPPDMDDPPDMDDPPDMDD 騰盛博藥 Zhi HONG Robert Taylor NELSEN Martin J MURPHY JRGrace Hui TANGGregg Huber ALTON • PO Box 309, Ugland HouseGrand Cayman KY1 – 1104Cayman Islands Grace Hui TANG 173100192 Martin J MURPHY JRGrace Hui TANG Gregg Huber ALTONZhi HONGMartin J MURPHY JR WeWork One City CenterSuite 05-110, 110 N Corcoran StDurham, NC 27701United States of America Robert Taylor NELSENGregg Huber ALTON 3485 1617 First Citizens Bank Maples Fund Services (Cayman) LimitedPO Box 1093, Boundary HallCricket SquareGrand Cayman KY1-1102Cayman Islands www.briibio.com 2137 2021713 Maples and Calder (Hong Kong) LLP HBVVirVBI2023HBVHBVVIR-2218(BRII-835)(BRII-877)HBV HBV1964HBsHBVHBV HBVHBVHBVBRII-179PreHevbri®20237BRII-179HBVPreHevbri®PreHevbri® HBVPPD/MDDBRII-296PPDMDDBRII-2971 HIVHIVBRII-732BRII-753 MDR/XDRBRII-693BRII-636BRII-672QpexQpexQPX772824BRII-693INDBRII-693 2023 oVirHBVoPreHevbri®oBRII-296PPD/MDDBRII-297oHIVHIVoo 10HBVPPD/MDDHBV (i)(ii)BRII-179BRII-693 HBVBRII-179HBVPreHevbri®HBVMDR/XDRBRII-693 HBVVBIVir HBVHBVHBVBRII-179(VBI-2601)BRII-835(VIR-2218)BRII-877(VIR-3434) 20237VBIHBVBRII-179(VBI-2601)PreHevbri® BRII-179 (VBI-2601)BRII-835 (VIR-2218)騰盛博藥 BRII-179(VBI-2601)HBVPre-S1Pre-S2SHBVBT BRII-835 (VIR-2218)HBVRNAN(GalNAc)siRNA BRII-179(VBI-2601)BRII-835(VIR-2218)HBVsiRNAHBV •202322023APASLBRII-835(VIR-2218)BRII-179(VBI-2601)BRII-835(VIR-2218)BRII-179(VBI-2601)HBsAgHBsAgTAPASL50HBsAg-1.7-1.8log10IU/mL40HBsAgHBsAgT 2023BRII-179 (VBI-2601)/BRII-835 (VIR-2218)2 BRII-179 (VBI-2601)PEG-IFN-α騰盛博藥 BRII-179 (VBI-2601)PEG-IFN-αBRII-179 (VBI-2601)HBVNRTIPEG-IFN-α •20237VBIBRII-179 (VBI-2601)•2022122120PEG-IFN-αNRTIHBVBRII-179 (VBI-2601) •2023924362426.3%15BRII-179/PEG-IFNαHBsAgPEG-IFNα19.3%11HBsAg361224.6%14BRII-179/PEG-IFNαHBsAgPEG-IFNα14.0%8HBsAg2432.6%15BRII-179/PEG-IFNαHBsAgPEG-IFNα21.6%11HBsAg3631.8%1414.9%7HBsAgBRII-179/PEG-IFNαHBsAg15924HBsAgPEG-IFNαHBsAg111HBsAg24BRII-179/PEG-IFNαPEG-IFNαBRII-179 •20242 VIR-2218 (BRII-835)PEG-IFN-α •20236Vir2023™2244848PEG-IFN-αVIR-2218 (BRII-835) 244816% (5/31)24HBsAg •HBs500mIU/mL424HBsAgHBs•20238BRII-835 (VIR-2218)PEG-IFN-α2 •BRII-835(VIR-2218)PEG-IFN-αBRII-179HBsAg VIR-2218 (BRII-835)BRII-877 (VIR-3434)VirMARCH BRII-877(VIR-3434)HBV10HBVBRII-877 (VIR-3434)XencorXtend™FcHBVT •20236Vir2023™2MARCHAVIR-2218(BRII-835)VIR-3434(BRII-877)HBVHBsAg2.7-3.1 log10IU/mL90%HBsAg10 IU/mL •NRTIHBsAg100IU/mLHBsAg1 log10IU/mLHBV DNALLOQHBeAgALT267%(4/6)NRTI •VIR-2218(BRII-835)VIR-3434(BRII-877)1 •2023™VirHBVVIR-3434(BRII-877)1VIR-3434(BRII-877) •HBsAg300 mgVIR-3434 (BRII-877)6 mg18 mg75 mg •VIR-3434 (BRII-877)HBsAg •2023Vir2MARCHBVIR-2218 (BRII-835)VIR-3434(BRII-877)PEG-IFN-αPEG-IFN-α•騰盛博藥BRII-877 (VIR-3434)12023 PreHevbri® PreHevbri®HBVPreHevbrio®PreHevbri®Sci-B-Vac®3PROTECTCONSTANTHBVEngerix-BPreHevbri®1858PreHevbri® •20237騰盛博藥VBIPreHevbri® •20236VBI3PROTECTHBVPreHevbrio®3.5PreHevbrioBRII-179 (VBI-2601)HBVPreS1PreS2S •Engerix-B®PreHevbrioHBsAg(P<0.0001) •PreHevbrioPre-S1Pre-S2THBs•3.5PreHevbrioHBsEngerix-B5.1(1,287 vs. 254mIU/mL)Engerix-BPreHevbrioT •PreHevbri® BRII-296BRII-297 BRII-296PPD/MDDAPPD/MDD •BRII-296PPD2POCFDA •2023BRII-296PPD2•BRII-2962024 BRII-297 •20236BRII-2971BRII-297 HIV BRII-732HIVBRII-753HIVHIVHIV BRII-732NCEEFdAHIVBRII-732NRTTIHIV •2023騰盛博藥BRII-7321FDAislatravir202212 •BRII-732HIV BRII-753NCEBRII-753HIVBRII-753 MDR/XDR BRII-693MDR/XDRBRII-693BRII-693MDR/XDR 20236BRII-693QpexShionogiBRII-693BRII-693 FDABRII-693QIDPFDA •20236BRII-693•20234BRII-693IND •BRII-693IND NTMAN2 騰盛博藥AN2epetraborole(BRII-658)NTMLeuRSepetraborole (BRII-658) •A N 21 0 0epetraborole (BRII-658)MAC2/3•AN2202392/32320242 •20237David MargolisLiYanMargolis騰盛博藥 •2023Maternal Mental Health ForumBlack Maternal Mental Health Week2023ClimbOutof the Darkness(PostpartumSupport International)36AnnualPSI ConferenceMind the Gap CNSHIVHBVMDR/XDRCOVID-19 CROCMO CDMO Zhi HongDavid MargolisCNSAleksandar SkubanJi Ma 2023630202.2 20237PreHevbri®PreHevbri® HBV 2023 oVirHBVoPreHevbri®oBRII-296PPD/MDDBRII-297oHIVHIVoo 20237騰盛博藥VBIHBVVBI騰盛博藥HBV 騰盛博藥BRII-179(VBI-2601)HBVHBVHBVBRII-179 騰盛博藥PreHevbri®PreHevbri®3HBVVBI騰盛博藥155BRII-179(VBI-2601)PreHevbri®騰盛博藥VBI3VBIBRII-179(VBI-2601)PreHevbri®7 202376 20238237410,152,500742,161,5003,369,500363,500ZhiHong545,000144,500 20238232023825 1. 2 0 2 363 00 . 6COVID-19 2. 202263038.247.7202363085.936.111.6 3. 202263034.057.3202363023.3 4. 202263022.818.320236304.5 5. 2022630258.556.32023630202.259.79.1 6. 202263095.57.32023630102.84.6202263063.21.8202363065.0 7. 2023630202212312,999.32,740.9 8. 9. (1) (2)100% 10. 2023630 2023630 2023630168.0 11. 20236302023630 12. 202363020221231 13. 202363040.6%40.4%19.0% 14. 20236301332023630 2023630155.02022630157.4 15. 2021713
